The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.
The test may mitigate potential interference during immunofixation tests that measure a patient’s response to a multiple myeloma therapy.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
Cellsearch is the only FDA-cleared circulating tumor cell test and is used to help manage patients with metastatic breast, prostate, and colorectal cancers.